Comparing the current results to its competitors, Centogene N V reported Revenue increase in the 4 quarter 2023 by 2.16 % year on year. The revenue growth was below Centogene N V 's competitors' average revenue growth of 5.93 %, achieved in the same quarter.
Centogene N V 's Comment on Competition and Industry Peers
The company operates in the rare disease information market and faces competition from other companies developing similar products and solutions. Increased competition may impact the company's revenue and access to research and patient data. Additionally, the company's strategic collaboration with Takeda may lead some pharmaceutical partners or clients, particularly those competing with Takeda, to seek alternative partnerships, which could negatively affect the company's business and operational results.
May 14, 2024
Centogene N.V. (NASDAQ: CNTG), a pioneering figure offering data-driven solutions in rare and neurodegenerative diseases, in partnership with Evotec SE (Frankfurt Stock Exchange: EVT; MDAX/TecDAX; NASDAQ: EVO; ISIN: DE0005664809), made a groundbreaking announcement on May 14, 2024, from their respective headquarters in Cambridge, Massachusetts, Rostock, Germany, and Berlin. The life sciences partner and the biotechnology manufacturer have collaboratively discovered a novel, potentially game-changing, small molecule with immense promise in treating neuronopathic Gaucher disease, primarily affecting patients diagnosed with type 2 and type 3 of the disease.Gaucher disease is a rare genetic disorder that results...
February 28, 2024
In a significant development, Centogene N.V., a leading provider of data-driven solutions in rare and neurodegenerative diseases, has recently announced its decision to explore various strategic alternatives aimed at delivering long-term value for its stakeholders. Based in Cambridge, Massachusetts, with operations in Rostock, Germany, and Berlin, the Company is well-positioned to leverage its expertise and technology to drive innovation in the healthcare sector. This article aims to outline the facts surrounding Centogene s strategic exploration and assess the potential impact on the company moving forward.Background and Context:Centogene N.V. has established itself as an essential life science partner, uti...
January 25, 2024
In the world of rare diseases, where finding effective treatments is often a challenging and time-consuming endeavor, a recent collaboration between CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine comes as a ray of hope. The joint efforts of both organizations aim to leverage diversified data for accelerating drug discovery and clinical development in the field of rare diseases. This groundbreaking partnership has the potential to de-risk the process and bring new opportunities for patients suffering from these often-neglected conditions. Unveiling the Collaboration:CENTOGENE, a global leader in the field of rare diseases diagnostics, has joined hands with the renown...
January 23, 2024
Parkinson s Disease (PD) is a chronic neurological disorder that affects millions of people worldwide, causing tremors, stiffness, and difficulties in motor function. Despite extensive research, the exact causes of PD still remain elusive. However, recent advancements in the field of genetics have opened up new possibilities for understanding the underlying genetic risk factors of PD. In this groundbreaking research study, CENTOGENE, a leading genomics company, has joined hands with The Michael J. Fox Foundation to launch a collaborative project aimed at validating the role of the GBA gene in Parkinson s Disease through the application of multiomics approaches.Unraveling the GBA Gene Mystery:Glucocerebrosida...
CENTOGENE N.V., the data-driven powerhouse endeavoring to decode rare and neurodegenerative diseases, today revealed that it has successfully reached its first recruitment and genetic testing milestone in the EFRONT Study. Presently underway, this study is designed explicitly to enhance the genetic comprehension of Frontotemporal Dementia (FTD). FTD, a category of diseases characterized by progressive neuronal decline, predominantly affects the frontal and temporal lobes of the brain. It is marked as one of the most familiar causes of dementia in younger adults. The EFRONT Study aims to further explain the genetic blueprint of FTD and potentially open the door to an array of new therapeutic avenues....
Biocept Inc is a molecular diagnostics company that specializes in developing and commercializing liquid biopsy tests. Their business model revolves around utilizing their proprietary technologies to detect and analyze biomarkers in blood samples, enabling physicians to make more informed treatment decisions for patients with cancer. They collaborate with various pharmaceutical and biotech companies to conduct clinical studies and molecular testing, offering their expertise and services in the field of precision medicine.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Sources:
Centogene N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Centogene N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
